OVERVIEW

Oncology Pharmacy Consults: Evolving Therapies for Advanced or Metastatic Breast Cancer: A Focus on CDK 4/6 Inhibition is organized by Power-Pak C.E. - Continuing Education for Pharmacists & Pharmacy Technicians and will be held from Nov 15, 2018 - Nov 15, 2019.

This CEU Conference has been approved for a maximum of 1.0 contact hour of credit (0.10 CEU).

Target Audience:
This enduring case-based activity is designed for oncology, health system, managed care, specialty pharmacists and other pharmacists who manage patients receiving systemic therapy for HR+ breast cancer. No prerequisites required.

Goal:
After completing this activity, pharmacists will have learned how CDK4/6 inhibitors positively affect HR+, HER-negative breast cancer care. Pharmacists will be able to offer expert advice on administration, drug interactions, and adverse effect management.

Overview:
Drug resistance to endocrine therapy is inevitable in patients with advanced or metastatic hormone-receptor positive (HR+) breast cancer. The number of patients with HR+ tumors is anticipated to increase in the next 15 years, driving the number of breast cancer cases up by 50%, and it can be challenging to treat patients with conventional hormonal and chemotherapy. Advances in recent years have identified key pathways responsible for hormone resistance. With the knowledge that pathways downstream of the hormone receptors are activated in patients with metastatic, endocrine therapy resistant disease, cyclin-dependent kinase (CDK) 4/6 inhibitors were developed. Many experts consider these novel targeted therapies potentially practice changing, and the role of CDK 4/6 inhibitors has been recently incorporated into the National Comprehensive Cancer Network's Clinical Practice Guidelines. The role of these agents now includes options in the first- and second-line settings in combination with endocrine therapy and as monotherapy. While similar, these agents have important differences. Pharmacists are an important part of the multidisciplinary healthcare team, often participating in key medication management strategies such as drug selection, drug dosing, management of adverse drug reactions, and patient education. Pharmacist involvement in oral chemotherapy programs has increased and has demonstrated positive outcomes. As the role of CDK4/6 inhibitors continues to expand, pharmacists will be called upon to provide expert opinions on the use of these agents. Presented in an interactive, case-based format, this activity is will contrast the mechanisms of action, dosing, efficacy, and toxicity of abemaciclib, ribociclib, and palbociclib in treating patients with metastatic breast cancer.

Learning Objectives:
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:
• Describe the mechanism of action and rationale for use of CDK 4/6 inhibitors in the treatment of HR+ breast cancer (BC).
• Apply the clinical trial data for CDK 4/6 inhibitors when developing pharmacotherapy plans for patients with HR+ breast cancer.
• Manage the adverse events associated with each CDK 4/6 inhibitor.

Additional details will be posted as soon as they are available.